Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Geron Corporation

Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Geron Corporation

PR Newswire

WAYNE, Pa., March 26, 2014

WAYNE, Pa., March 26, 2014 /PRNewswire/ --Ryan & Maniskas, LLP announces that
a class action lawsuit has been filed in the United States District Court for
the Northern District of California on behalf of purchasers the securities of
Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) between June 16,
2013 and March 11, 2014, inclusive (the "Class Period").

Ryan & Maniskas, LLP.

For more information regarding this class action suit, please contact Ryan &
Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by
email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/gern.

The complaint charges Geron and certain of its executives with violations of
federal securities laws. Specifically, the complaint alleges that Geron
misrepresented and/or failed to disclose: (1) persistent low-grade liver
function test abnormalities had been observed in the Phase 2 study of its drug
imetelstat in essential thrombocythemia or polycythemia vera patients; (2)
there was a high risk of potential chronic livery injury following long-term
exposure to the drug, and (3) as a result of the foregoing, defendants'
positive statements about the prospects for imetelstat lacked a reasonable
basic and/or were materially false and misleading.

On March 12, 2014, the Company announced it had received a verbal notice from
the U.S. Food and Drug Administration ("FDA") that a clinical hold would be
placed on imetelstat clinical trials.

On this news, shares of Geron fell over 60% to close at $1.69 per share.

If you are a member of the class, you may, no later than May 13, 2014, request
that the Court appoint you as lead plaintiff of the class. A lead plaintiff
is a representative party that acts on behalf of other class members in
directing the litigation. In order to be appointed lead plaintiff, the Court
must determine that the class member's claim is typical of the claims of other
class members, and that the class member will adequately represent the class.
Under certain circumstances, one or more class members may together serve as
"lead plaintiff." Your ability to share in any recovery is not, however,
affected by the decision whether or not to serve as a lead plaintiff. You may
retain Ryan & Maniskas, LLP or other counsel of your choice, to serve as your
counsel in this action.

For more information about the case or to participate online, please visit:
www.rmclasslaw.com/cases/gern, or contact Richard A. Maniskas, Esquire
toll-free at (877) 316-3218, or by e-mail at rmaniskas@rmclasslaw.com. For
more information about class action cases in general or to learn more about
Ryan & Maniskas, LLP, please visit our website: www.rmclasslaw.com.

CONTACT: Ryan & Maniskas, LLP
          Richard A. Maniskas, Esquire
          995 Old Eagle School Rd., Suite 311
          Wayne, PA 19087
          877-316-3218
          rmaniskas@rmclasslaw.com
          www.rmclasslaw.com/cases/gern

Logo- http://photos.prnewswire.com/prnh/20121112/MM11729LOGO

SOURCE Ryan & Maniskas, LLP

Website: http://www.rmclasslaw.com
 
Press spacebar to pause and continue. Press esc to stop.